Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.

Cytotherapy - 1 Jan 2016

Masuyama Jun-ichi, Murakami Takashi, Iwamoto Sanju, Fujita Sanehiko

Abstract excerpt

BACKGROUND AIMS: This study developed a new method to expand CD3(-)CD56(+) natural killer (NK) cells from human peripheral blood mononuclear cells (PBMCs) without feeder cells for clinical trials. METHODS: PBMCs from healthy subjects were co-stimulated with anti-CD3 and anti-CD52 monoclonal antib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to CD3 Complex
Share to CD4-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Separation

Share to Cytotoxicity, Immunologic

Share to Interferon-gamma

Share to K562 Cells

Share to Killer Cells, Natural

Source

Identifiers

PMID: 26549384
DOI: 10.1016/j.jcyt.2015.09.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-26549384-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.PMID 26549384Read ↗

Autologous Natural Killer Cell-enrichment for Immune Cell Therapy: Preclinical Setting Phase, Shiraz Experience.Semantic proximity Read ↗

Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.Semantic proximity Read ↗

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components.Semantic proximity Read ↗

Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK cells with Enhanced Antitumor Activity.Semantic proximity Read ↗

Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesSemantic proximity Read ↗

Enhancement of NK cell proliferation by activation pre-processing of autologous feeder cell before irradiationSemantic proximity Read ↗

Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activitySemantic proximity Read ↗

Bringing natural killer cells to the clinic: ex vivo manipulationSemantic proximity Read ↗

Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients.Semantic proximity Read ↗

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.Semantic proximity Read ↗

The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancerSemantic proximity Read ↗

A Novel Feeder cell based on 4-1BBL and Membrane-bound IL-21/ IL-15 Induce Highly Expansion and Anti-tumor Effect of Natural Killer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.